CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) May 19, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 â 8, 2021.
âWe are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this yearâs ASCO, including multiple novel combinations of tislelizumab with our investigational Fc-competent anti-TIGIT-antibody ociperlimab and other therapeutic agents, and the ongoing evaluation of our next-generation BTK inhibitor zanubrutinib,â commented Lai Wang, Ph.D., Global Head of R&D at BeiGene. âWe believe that these presentations underscore the breadth and diversity, as well as the remarkable progress and momentum, in BeiGeneâ�
Cisco Launches Digitization Program in South Korea to Accelerate Digital Transformation and Support Inclusive Pandemic Recovery
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
Atlanta Korean community is outraged, says issue isn t actually complex
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.